ClinicalTrials.gg
CompletedNCT04516967Updated Jun 3, 2026Results posted

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

A Phase 3 interventional study of Avatrombopag and Placebo in Immune Thrombocytopenia, sponsored by Sobi, Inc.. Completed at 62 sites in 9 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Sobi, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
4th of 16
75 · median 53
Started
2021
with 3 others
Phase 3
6 of 16
1 open now
Registered
8th of 16
by date
Lead sponsor
4 of 16
Sobi, Inc.

Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 8th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months

Read the detailed description

Subjects will be randomized in to blinded therapy of avatrombopag or placebo in a 3:1 ratio for a period of 12 weeks. Subjects who complete the 12 week treatment period and are eligible may continue to the open label extension phase which will last 2 years.

03

Conditions studied

  • Immune Thrombocytopenia

Keywords

  • ITP
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants ≥1 and \<18 years of age at Screening and Baseline with a diagnosis of primary ITP for ≥6 months duration and has had an insufficient response to a previous treatment, in the opinion of the Investigator.
  • Participant has an average of 2 counts \<30×10\^9/L with no single count >35×10\^9/L in the screening period

Exclusion criteria

Exclusion Criteria:

  • Participants must not have a known history of secondary ITP, any history of arterial or venous thrombosis, including partial or complete thrombosis, known inherited thrombocytopenia, a history of myelodysplastic syndrome (MDS) or known history of congenital heart abnormalities or arrhythmias.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Experimental: Avatrombopag Double Blind

    Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks

    Drug: Avatrombopag

  • Placebo comparator
    Placebo Comparator:Placebo Double Blind

    Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks

    Drug: Placebo

  • Experimental
    Avatrombopag Open Label Extension

    Investigational product administered orally for up to 2 years.

    Drug: Avatrombopag

Interventions

  • Oral avatrombopag tablet or sprinkle capsule

    Also known as: Doptelet

  • DrugPlacebo

    Placebo comparator tablet or sprinkle capsule

06

What researchers measure

Primary outcomes

  1. Durable Platelet Response

    The proportion of subjects achieving at least 6 out of 8 weekly platelet counts ≥50×10\^9/L during the last 8 weeks of the 12 week Treatment Period in the Core Phase, in the absence of rescue medication

    Time frame: Last 8 weeks of 12 week treatment regimen

  2. Alternative Primary: Platelet Response

    The proportion of subjects for whom at least 2 consecutive platelet assessments are ≥50×10\^9/L over the 12 weeks of treatment in the Core Phase in the absence of rescue medication.

    Time frame: 12 weeks of treatment

Secondary outcomes

  1. Percentage of Weeks Platelet Count ≥50×10^9/L

    The percentage of weeks subjects have a platelet count ≥50×10\^9/L during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.

    Time frame: 12 weeks of treatment

  2. Platelet Response at Day 8

    The proportion of subjects with a platelet count ≥50×10\^9/L at day 8, in the absence of rescue therapy.

    Time frame: Day 8

  3. Percentage of Weeks Platelet Count Between ≥50×10^9/L and ≤150×10^9/L

    The percentage of weeks subjects have a platelet count between ≥50×10\^9/L and ≤150×10\^9/L, during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.

    Time frame: 12 weeks of treatment

  4. Rescue Medications

    The proportion of subjects who require rescue medications during 12 weeks of treatment in the Core Phase of the study.

    Time frame: 12 weeks of treatment

  5. Incidence of Any Bleeding Event (WHO Grade 1-4)

    Overall incidence of bleeding events associated with ITP measured using the WHO Bleeding Scale (Grade 1-4).

    Time frame: 12 weeks of treatment

07

Results

Posted Jan 17, 2025

Participant flow

Core Phase
Participant flow — Core Phase
MilestoneExperimental: Avatrombopag Double BlindPlacebo Comparator:Placebo Double BlindAvatrombopag Open Label Extension
Started54210
Completed4410
Not completed10200
Withdrew: Adverse event210
Withdrew: Physician decision110
Withdrew: Lack of efficacy7180
Extension Phase
Participant flow — Extension Phase
MilestoneExperimental: Avatrombopag Double BlindPlacebo Comparator:Placebo Double BlindAvatrombopag Open Label Extension
Started0073
Completed0049
Not completed0024
Withdrew: Withdrawal by subject003
Withdrew: Subject noncompliance001
Withdrew: Adverse event005
Withdrew: Sponsor request006
Withdrew: Lack of efficacy009

Outcome measures

PrimaryDurable Platelet Response

The proportion of subjects achieving at least 6 out of 8 weekly platelet counts ≥50×10\^9/L during the last 8 weeks of the 12 week Treatment Period in the Core Phase, in the absence of rescue medication

Time frame:
Last 8 weeks of 12 week treatment regimen
Reported as:
Count of participants · Participants
Durable Platelet Response
ParticipantsExperimental: AvatrombopagPlacebo Comparator:Placebo
Durable Platelet Response150
Statistical analysis
  • Experimental: Avatrombopag vs Placebo Comparator:Placebo · Fisher Exact · p = 0.0077
PrimaryAlternative Primary: Platelet Response

The proportion of subjects for whom at least 2 consecutive platelet assessments are ≥50×10\^9/L over the 12 weeks of treatment in the Core Phase in the absence of rescue medication.

Time frame:
12 weeks of treatment
Reported as:
Count of participants · Participants
Alternative Primary: Platelet Response
ParticipantsExperimental: AvatrombopagPlacebo Comparator:Placebo
Alternative Primary: Platelet Response440
Statistical analysis
  • Experimental: Avatrombopag vs Placebo Comparator:Placebo · Fisher Exact · p = <0.0001
SecondaryPercentage of Weeks Platelet Count ≥50×10^9/L

The percentage of weeks subjects have a platelet count ≥50×10\^9/L during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.

Time frame:
12 weeks of treatment
Reported as:
Mean · percentage of weeks
Percentage of Weeks Platelet Count ≥50×10^9/L
percentage of weeksExperimental: AvatrombopagPlacebo Comparator:Placebo
Percentage of Weeks Platelet Count ≥50×10^9/L48.9 ± 25.221.2 ± 3.92
Statistical analysis
  • Experimental: Avatrombopag vs Placebo Comparator:Placebo · t-test, 2 sided · p = <0.0001
SecondaryPlatelet Response at Day 8

The proportion of subjects with a platelet count ≥50×10\^9/L at day 8, in the absence of rescue therapy.

Time frame:
Day 8
Reported as:
Count of participants · Participants
Platelet Response at Day 8
ParticipantsExperimental: AvatrombopagPlacebo Comparator:Placebo
Platelet Response at Day 8300
Statistical analysis
  • Experimental: Avatrombopag vs Placebo Comparator:Placebo · Fisher Exact · p = <0.0001
SecondaryPercentage of Weeks Platelet Count Between ≥50×10^9/L and ≤150×10^9/L

The percentage of weeks subjects have a platelet count between ≥50×10\^9/L and ≤150×10\^9/L, during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.

Time frame:
12 weeks of treatment
Reported as:
Mean · percentage of weeks
Percentage of Weeks Platelet Count Between ≥50×10^9/L and ≤150×10^9/L
percentage of weeksExperimental: AvatrombopagPlacebo Comparator:Placebo
Percentage of Weeks Platelet Count Between ≥50×10^9/L and ≤150×10^9/L29.2 ± 19.641.2 ± 3.92
Statistical analysis
  • Experimental: Avatrombopag vs Placebo Comparator:Placebo · t-test, 2 sided · p = <0.0001
SecondaryRescue Medications

The proportion of subjects who require rescue medications during 12 weeks of treatment in the Core Phase of the study.

Time frame:
12 weeks of treatment
Reported as:
Count of participants · Participants
Rescue Medications
ParticipantsExperimental: AvatrombopagPlacebo Comparator:Placebo
Rescue Medications49
Statistical analysis
  • Experimental: Avatrombopag vs Placebo Comparator:Placebo · Fisher Exact · p = 0.0008
SecondaryIncidence of Any Bleeding Event (WHO Grade 1-4)

Overall incidence of bleeding events associated with ITP measured using the WHO Bleeding Scale (Grade 1-4).

Time frame:
12 weeks of treatment
Reported as:
Count of participants · Participants
Incidence of Any Bleeding Event (WHO Grade 1-4)
ParticipantsExperimental: AvatrombopagPlacebo Comparator:Placebo
Incidence of Any Bleeding Event (WHO Grade 1-4)4519
Statistical analysis
  • Experimental: Avatrombopag vs Placebo Comparator:Placebo · Fisher Exact · p = 0.7175

Adverse events

Collected over Up to 12 weeks (Core Phase) and up to 2 years (Extension Phase). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Avatrombopag0/54 (0%)5/54 (9.3%)50/54 (92.6%)
Placebo Comparator:Placebo0/21 (0%)1/21 (4.8%)16/21 (76.2%)
Open Label Extension Phase0/73 (0%)22/73 (30.1%)71/73 (97.3%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventExperimental: AvatrombopagPlacebo Comparator:PlaceboOpen Label Extension Phase
EpistaxisRespiratory, thoracic and mediastinal disorders1/540/214/73
ThrombocytopeniaBlood and lymphatic system disorders0/540/214/73
Mouth HaemorrhageGastrointestinal disorders1/541/210/73
Skin HaemorrhageSkin and subcutaneous tissue disorders0/541/210/73
ThrombocytosisBlood and lymphatic system disorders1/540/212/73
Mucosal HaemorrhageGeneral disorders0/540/212/73
GastroenteritisInfections and infestations0/540/212/73
Immune ThrombocytopeniaBlood and lymphatic system disorders1/540/211/73
Oral PurpuraGastrointestinal disorders1/540/210/73
Rectal HaemorrhageGastrointestinal disorders1/540/211/73
Most frequent other events
Showing 10 of 41
Most frequent other events
EventExperimental: AvatrombopagPlacebo Comparator:PlaceboOpen Label Extension Phase
Upper Respiratory Tract InfectionInfections and infestations6/542/2130/73
PetechiaeSkin and subcutaneous tissue disorders14/546/219/73
CoughRespiratory, thoracic and mediastinal disorders9/540/2120/73
PyrexiaGeneral disorders9/540/2118/73
HeadacheNervous system disorders10/544/2117/73
EpistaxisRespiratory, thoracic and mediastinal disorders12/544/2117/73
EcchymosisSkin and subcutaneous tissue disorders10/541/219/73
NasopharyngitisInfections and infestations4/540/2113/73
DiarrhoeaGastrointestinal disorders4/540/2112/73
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders7/540/2112/73

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental: AvatrombopagPlacebo Comparator:PlaceboTotal
Mean8.9 ± 4.369.9 ± 4.139.2 ± 4.29
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: AvatrombopagPlacebo Comparator:PlaceboTotal
Female241236
Male30939
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: AvatrombopagPlacebo Comparator:PlaceboTotal
Hispanic or Latino325
Not Hispanic or Latino501565
Unknown or Not Reported145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: AvatrombopagPlacebo Comparator:PlaceboTotal
American Indian or Alaska Native000
Asian314
Native Hawaiian or Other Pacific Islander000
Black or African American000
White481563
More than one race000
Unknown or Not Reported358
Region of Enrollment
Region of Enrollment(participants)Experimental: AvatrombopagPlacebo Comparator:PlaceboTotal
Turkey20929
Hungary415
United States8513
Ukraine202
Poland314
United Kingdom11213
France011
Germany213
Russia415
08

Study locations

62 sites
  • Site 112
    Phoenix, Arizona 85016, United States
  • Site 103
    Long Beach, California 90806, United States
  • Site 119
    Orange, California 92868, United States
  • Site 109
    Sacramento, California 95817, United States
  • Site 101
    San Francisco, California 94158, United States
  • Site 111
    Aurora, Colorado 80045, United States
  • Site 120
    Wilmington, Delaware 19803, United States
  • Site 117
    Gainesville, Florida 32610, United States
  • Site 116
    Atlanta, Georgia 30322, United States
  • Site 107
    Peoria, Illinois 61615, United States
  • Site 104
    Boston, Massachusetts 02115, United States
  • Site 105
    Minneapolis, Minnesota 55404, United States
  • Site 114
    Jackson, Mississippi 39216, United States
  • Site 102
    Las Vegas, Nevada 89135, United States
  • Site 108
    Morristown, New Jersey 07960, United States
  • Site 118
    Charlotte, North Carolina 28203, United States
  • Site 113
    Durham, North Carolina 27710, United States
  • Site 106
    Columbus, Ohio 43205, United States
  • Site 121
    Philadelphia, Pennsylvania 19104, United States
  • Site 110
    Providence, Rhode Island 02903, United States
  • Site 115
    Houston, Texas 77030, United States
  • Site 201
    Toulouse, Occitanie 31059, France
  • Site 202
    Paris, Île-de-France Region 75019, France
  • Site 301
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Site 302
    Hamburg, Free and Hanseatic City of Hamburg 20246, Germany
  • Site 303
    Kiel, Schleswig-Holstein 24105, Germany
  • Site 304
    Berlin, State of Berlin 13353, Germany
  • Site 801
    Budapest, 1094, Hungary
  • Site 802
    Miskolc, 3526, Hungary
  • Site 803
    Pécs, 7623, Hungary
  • Site 502
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-667, Poland
  • Site 503
    Warsaw, Masovian Voivodeship 02-091, Poland
  • Site 505
    Zabrze, Silesian Voivodeship 41-800, Poland
  • Site 501
    Olsztyn, Warmian-Masurian Voivodeship 10-561, Poland
  • Site 504
    Lodz, Łódź Voivodeship 91-738, Poland
  • Site 907
    Chelyabinsk, 454076, Russia
  • Site 904
    Moscow, 117198, Russia
  • Site 906
    Moscow, 117997, Russia
  • Site 901
    Moscow, 119049, Russia
  • Site 902
    Nizhny Novgorod, 603136, Russia
  • Site 905
    Saint Petersburg, 197022, Russia
  • Site 903
    Volgograd, 400138, Russia
  • Site 701
    Adana, 01330, Turkey (Türkiye)
  • Site 704
    Ankara, 06230, Turkey (Türkiye)
  • Site 706
    Antalya, 07059, Turkey (Türkiye)
  • Site 702
    Antalya, 07160, Turkey (Türkiye)
  • Site 705
    Denizli, 20160, Turkey (Türkiye)
  • Site 709
    Istanbul, 34093, Turkey (Türkiye)
  • Site 710
    Istanbul, 34093, Turkey (Türkiye)
  • Site 703
    Istanbul, 34764, Turkey (Türkiye)
  • Site 707
    Izmir, 35100, Turkey (Türkiye)
  • Site 708
    Mersin, 33110, Turkey (Türkiye)
  • Site 954
    Kharkiv, Kharkiv Oblast 61000, Ukraine
  • Site 952
    Vinnytsia, 21029, Ukraine
  • Site 405
    Birmingham, England B4 6NH, United Kingdom
  • Site 408
    Liverpool, England L12 2AP, United Kingdom
  • Site 403
    London, England SE5 9RS, United Kingdom
  • Site 410
    London, England W12 0HS, United Kingdom
  • Site 407
    London, England WC1N 3JH, United Kingdom
  • Site 402
    Manchester, England M13 9WL, United Kingdom
  • Site 401
    Sheffield, England S10 2TH, United Kingdom
  • Site 406
    Cardiff, Wales CF14 4XW, United Kingdom
09

References and documents

Publications

  • Leblebisatan, G. G., Aydinok, Y., Äcenal, Ş., Grainger, J., Grimes, A., Lambert, M., Zhang, J., Jamieson, B., Vredenburg, M., & Kolodny, S. (2025). PB0364: Evaluation of efficacy and safety of avatrombopag in children with ITP based on disease duration. RPTH, 9(Suppl 2).
  • Leblebisatan, G. G., Aydinok, Y., Ünal Cangül, Ş., Grainger, J., Grimes, A., Lambert, M., Zhang, J., Jamieson, B., Vredenburg, M., & Kolodny, S. (2025). PB0348: Consistent response to avatrombopag for pediatric ITP across various baseline characteristics. RPTH, 9(Suppl 2).
  • Grace, R. F., Leblebisatan, G., Aydinok, Y., Ünal Cangül, Ş., Grainger, J., Zhang, J., Alkhori Franzén, L., & Skuban, N. (2025). PS2234: Efficacy and safety of avatrombopag for the treatment of pediatric immune thrombocytopenia in the open-label extension of a Phase 3, randomized, double-blind, placebo-controlled trial. HemaSphere, 9(Suppl 1), 4067.
  • Scott Kolodny, Rachael Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michelle Lambert, Jessica Zhang, Brian Jamieson, Michael Vredenburg. Baseline Correlates With Durability of Avatrombopag Response in Pediatric Immune Thrombocytopenia. Pediatr Blood Cancer. 2025;72(Suppl S94):e31765. Abstract [# 304].
  • Scott Kolodny, Rachael Grace, Göksel Leblebisatan, YesimAydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian Jamieson, Michael Vredenburg. Clinically Meaningful Response to Avatrombopag for Treatment of Pediatric Immune Thrombocytopenia. Pediatr Blood Cancer. 2025;72(Suppl S06):e31765. Abstract [# 2011].
  • Grace RF, Leblebisatan G, Aydinok Y, Unal S, Grainger JD, Zhang J, Smallwood L, de Leon E, Jamieson BD; AVA-PED-301 Study Group. Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study. Lancet Haematol. 2025 Jul;12(7):e494-e504. doi: 10.1016/S2352-3026(25)00107-3. Epub 2025 May 23. PubMed 40418942 ↗
  • Grace RF, Leblebisatan G, Aydinok Y, Unal S, Grainger JD, Zhang J, Smallwood L, de Leon E, Jamieson BD, DiRaimo J. Avatrombopag for treating children and adolescents with immune thrombocytopenia: a plain language summary. Expert Rev Hematol. 2026 Feb;19(2):107-116. doi: 10.1080/17474086.2025.2604524. Epub 2025 Dec 18. PubMed 41411046 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Nov 2023, 32 months.

Results were first posted in Jan 2025, 1 year 2 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 32 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Aug 18, 2020
StartActual
Mar 5, 2021
Primary completionActual
Nov 8, 2023
CompletionActual
Oct 28, 2025
Results first posted
Jan 17, 2025
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04516967
Lead sponsor
Sobi, Inc.
Responsible party
Sponsor
First posted
Aug 18, 2020
Start date
Mar 5, 2021
Primary completion
Nov 8, 2023
Completion
Oct 28, 2025
Results posted
Jan 17, 2025
Last update
Jun 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion